Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $54.00

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $54.00.

A number of research analysts recently weighed in on ARCT shares. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Citigroup restated a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 5th.

Arcturus Therapeutics Stock Down 2.3%

Shares of NASDAQ:ARCT traded down $0.30 during trading on Friday, reaching $12.85. 354,231 shares of the stock traded hands, compared to its average volume of 416,915. The stock has a 50-day moving average of $12.66 and a two-hundred day moving average of $13.85. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $25.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64. The stock has a market cap of $348.49 million, a P/E ratio of -5.08 and a beta of 2.27.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. As a group, sell-side analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors have recently bought and sold shares of the business. Deutsche Bank AG increased its stake in Arcturus Therapeutics by 42.7% in the 4th quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company's stock worth $420,000 after buying an additional 7,417 shares in the last quarter. Vanguard Group Inc. increased its stake in Arcturus Therapeutics by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock worth $28,587,000 after buying an additional 107,635 shares in the last quarter. GAMMA Investing LLC grew its stake in Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after acquiring an additional 5,085 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Arcturus Therapeutics by 52.7% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,461 shares of the biotechnology company's stock valued at $241,000 after acquiring an additional 4,647 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Arcturus Therapeutics by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company's stock valued at $9,421,000 after acquiring an additional 3,186 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.